Platelet News and Research

RSS

Patients taking warfarin who develop acute stroke more likely to experience brain hemorrhage

Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function appears normal, according to a report posted online today that will appear in the May print issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.

9 Mar 2010

Scientists discover genetic cause of Quebec Platelet Disorder

For some Canadians, any cut such as from dental work or surgery can cause days or more of bleeding. Although they are not hemophiliacs, for some an ordinary bruise can balloon into the size of an orange.

4 Mar 2010

Platelet function tests may predict heart attack, says study

An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a coronary stent implantation found that only three of the tests were associated with a modest ability to predict outcomes such as heart attack or death, according to a study in the February 24 issue of JAMA.

25 Feb 2010

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

Cerus Corporation announced today that investigators from blood centers in Sweden, Belgium, France and Slovenia will present their experience with the INTERCEPT Blood System for platelets and plasma during a leading international transfusion safety meeting, the XIIth International Haemovigilance Seminar taking place in Dubrovnik, Croatia from February 17 to 19.

18 Feb 2010

New research report on orthopedic biomaterials market in the U.S.

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for orthopedic biomaterials grew by 11.5% in 2009 and is estimated to reach almost $6.3 billion by 2016.

17 Feb 2010

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the April print issue of Archives of Dermatology, one of the JAMA/Archives journals.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Wednesday's blizzard-like conditions impacted blood donations across the area of Penn-Jersey Region

Wednesday's blizzard-like conditions have impacted blood donations across the area served by the Penn-Jersey Region. The American Red Cross expected to see 1,300 donors on Wednesday, however due to inclement weather all blood drives were cancelled.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang (EFS), for the development of the company's INTERCEPT Blood System for red blood cells.

10 Feb 2010

ASA Effect test: A tool to identify patients who do not respond to ASA therapy

A convenient test is now available in Canada that determines if the ASA a patient is taking to prevent heart attack and stroke is working. ASA Effect(TM) is offered through LifeLabs Medical Laboratory Services and its network of collection and testing centres.

10 Feb 2010

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Emerging Healthcare Solutions, Inc. announced today that management has formally delivered an actionable Term Sheet to ThromboVision for review and that follow up communications have been very favorable.

9 Feb 2010

Risk of heart attack greater in women with gout

Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases.

7 Feb 2010

Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.

4 Feb 2010

Platelet News and Research

Patients taking warfarin who develop acute stroke more likely to experience brain hemorrhage

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Scientists discover genetic cause of Quebec Platelet Disorder

Platelet function tests may predict heart attack, says study

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

New research report on orthopedic biomaterials market in the U.S.

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Wednesday's blizzard-like conditions impacted blood donations across the area of Penn-Jersey Region

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

ASA Effect test: A tool to identify patients who do not respond to ASA therapy

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Risk of heart attack greater in women with gout

Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

EPO to grant patent notice to BioMimetic Therapeutics

GMC designated as NMDP collection site to collect bone marrow from willing donors

Sports Medicine Clinic offers PRP therapy to heal injured ligaments, tendons and muscles

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News